[CLSTR]
API
< Back to all clusters
[BUSINESS] · France · 3 sources

France: Pharmaceutical labs seek price increase for paracetamol

paracetamol pharmaceutical industry France 2030 drug pricing pharmaceutical sovereignty

Pharmaceutical laboratories including UPSA and Opella are requesting an increase in the transfer price for paracetamol manufactured in France. The current price of 0.76 euro per box has been maintained by a moratorium in place since 2021, which is set to expire on December 31, 2026.

Industry representatives argue that a price hike of approximately 10 cents is necessary due to the higher costs associated with relocating production to France. Specifically, production at the Seqens plant in Isère is 60 percent more expensive than production in Asia. This relocation is part of the France 2030 plan aimed at increasing pharmaceutical sovereignty, as Europe currently relies on India and China for nearly 80 percent of its common medicinal active ingredients.

This request contrasts with previous considerations by the Economic Committee for Health Products (CEPS), which had explored lowering transfer prices by 10 cents to generate savings for the French Social Security system.

Entities

Economic Committee for Health Products · France · Opella · SEQENS · UPSA · ČEPS

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

Santé. Doliprane, Dafalgan... pourquoi le prix du paracétamol pourrait bientôt augmenter [www.bienpublic.com]
Santé. Doliprane, Dafalgan... pourquoi le prix du paracétamol pourrait bientôt augmenter [www.dna.fr]
Santé. Doliprane, Dafalgan... pourquoi le prix du paracétamol pourrait bientôt augmenter [www.lejsl.com]